Fact based stock research
Roche (SWX:ROG)


Roche stock research in summary

roche.com


Roche shares have a HOLD rating. While they show above average growth, they are bad value, and are riskily financed. We recommend holding Roche shares.


Latest Obermatt Ranks


Country Switzerland
Industry Pharmaceuticals
Index SMI, SPI
Size class XX-Large

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()




Research History: Roche

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
33
32
41
49
STOCK GROWTH RANKS
11
58
58
58
STOCK SAFETY RANKS
39
44
40
47
COMBINED STOCK RANKS
11
41
47
59

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Roche in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Roche; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
49
54
78
78
PROFIT GROWTH
33
62
62
59
STOCK RETURNS
32
29
45
45
CONSOLIDATED RANK: GROWTH
11
58
58
58

Financial reporting date of Growth Rank: 31-Dec-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Roche.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
44
50
52
57
REFINANCING
22
33
30
25
LIQUIDITY
54
53
61
61
CONSOLIDATED RANK: SAFETY
39
44
40
47

Financial reporting date of Safety Rank: 31-Dec-2017. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Roche and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Roche from June 8, 2018.